Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William H Chappell

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cell Cycle (Georgetown, Tex.)|August 27, 2011
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cellsLinda S Steelman, Patrick Navolanic, William H Chappell, et al.
Advances in Biological Regulation|June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Expert Opinion on Emerging Drugs|September 1, 2009
Emerging Raf inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Expert Opinion on Emerging Drugs|February 16, 2010
Emerging MEK inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Journal of Cellular Physiology|February 9, 2011
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A McCubrey, Linda S Steelman, C Ruth Kempf, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2012
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineWilliam H Chappell, Stephen L Abrams, Richard A Franklin, et al.
Biochimica Et Biophysica Acta|November 28, 2006
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Current Pharmaceutical Design|March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapyJames A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cell Cycle (Georgetown, Tex.)|August 27, 2011
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cellsLinda S Steelman, Patrick Navolanic, William H Chappell, et al.
Advances in Biological Regulation|June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Expert Opinion on Emerging Drugs|September 1, 2009
Emerging Raf inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Expert Opinion on Emerging Drugs|February 16, 2010
Emerging MEK inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Journal of Cellular Physiology|February 9, 2011
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A McCubrey, Linda S Steelman, C Ruth Kempf, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2012
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineWilliam H Chappell, Stephen L Abrams, Richard A Franklin, et al.
Biochimica Et Biophysica Acta|November 28, 2006
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Current Pharmaceutical Design|March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapyJames A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 4